BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7584099)

  • 1. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
    Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
    Jannot CB; Beerli RR; Mason S; Gullick WJ; Hynes NE
    Oncogene; 1996 Jul; 13(2):275-82. PubMed ID: 8710366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
    Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
    Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
    Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
    Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects.
    Wang-Johanning F; Gillespie GY; Grim J; Rancourt C; Alvarez RD; Siegal GP; Curiel DT
    Cancer Res; 1998 May; 58(9):1893-900. PubMed ID: 9581830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
    Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
    Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
    Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
    Barnes MN; Deshane JS; Siegal GP; Alvarez RD; Curiel DT
    Clin Cancer Res; 1996 Jul; 2(7):1089-95. PubMed ID: 9816272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
    Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
    Deshane J; Siegal GP; Wang M; Wright M; Bucy RP; Alvarez RD; Curiel DT
    Gynecol Oncol; 1997 Mar; 64(3):378-85. PubMed ID: 9062138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation.
    Grim JE; Siegal GP; Alvarez RD; Curiel DT
    Biochem Biophys Res Commun; 1998 Sep; 250(3):699-703. PubMed ID: 9784409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris.
    Hu S; Li L; Qiao J; Guo Y; Cheng L; Liu J
    Protein Expr Purif; 2006 May; 47(1):249-57. PubMed ID: 16403645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.